FindTrial
Sign In

Treatment outcomes of anti-VEGF therapy in patients with diabetic macular edema at a tertiary eye center

Treatment outcomes of anti-VEGF therapy in patients with diabetic macular edema at a tertiary eye center

Status
Active, not recruiting
Phases
Unknown
Study type
Observational
Source
TCTR
Registry ID
TCTR20230209002
Enrollment
200
Registered
2023-02-09
Start date
2016-01-01
Completion date
Unknown
Last updated
2026-08-03

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Diabetic macula edema Diabetic macula edema

Interventions

Baseline best-corrected visual acuity in EDTRS letters, Baseline central macula thickness (micron),Final best-corrected visual acuity in EDTRS letters at year1 and year2, Final central macula thickne
Treatment,Treatment
baseline anatomical and functional outcomes for DME, Final anatomical and functional outcomes for DME at year1 and year2

Sponsors

Novartis company
Lead Sponsor

Eligibility

Sex/Gender
All
Age
18 Years to No maximum

Inclusion criteria

Inclusion criteria: Patients at least 18 years old diagnosed with DME who attended the intravitreal clinic between 2016 and 2018

Exclusion criteria

Exclusion criteria: Patients below 18 years old loss following up

Design outcomes

Primary

MeasureTime frame
Best corrected visual acuity, Central subfield thickness year 1 , year 2 ETDRS in letters score, micron—

Secondary

MeasureTime frame
Correlation between Best corrected visual acuity and central subfield thickness Year 1, Year 2 ETDRS in letters core, micron—

Countries

Thailand

Contacts

Public ContactKarntida Chanwimol

Mettapracharak hospital

ckarntida@gmail.com0819320820

Outcome results

None listed

Source: TCTR (via WHO ICTRP) · Data processed: Aug 9, 2026